More M&A Deals Could Boost Biotech ETFs

By
Devon Layne
December 12, 2012
Share:

Amgen’s $415 million acquisition of DeCode suggests big-pharma will transition from blockbuster drugs to specialized medicines that target specific areas of the human body, a possibility that could bode well for the biotech sector and its ETFs, according to an article on ETF Trends.

The pursuit for targeted drugs could also benefit from the Obama administration’s push toward health care reform, as the extra insurance coverage would boost demand for medicines, the article said.

For investors seeking a doorway into biotech investments, consider these sector-covering ETFs as a starting point:

  • Market Vectors Biotech ETF (NYSEArca: BBH)
  • iShares Nasdaq Biotechnology ETF (NYSEArca: IBB)
  • First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT)

 

Head over to ETFtrends.com to learn more about ETFs within the biotech sector.

ETF DAILY DATA

The oil funds 'XOP' and 'OIH' gathered money on Thursday, April 16, helping lift total U.S.-listed ETF assets to a record $2.158 trillion.

'SPY,' 'LNK' and 'XOP' paced SSgA's issuer-leader inflows on Thursday, April 16, as total U.S.-listed ETF assets reached a record $2.158 trillion.

ETF.COM ANALYST BLOGS

By Olivier Ludwig

If you’re puzzled by Israel’s relatively strong stock market performance, don’t forget you’re taking measure of a developed country.

By Olivier Ludwig

If only Fidelity could speak freely about all the positive things it does for investors.

By Dave Nadig

Last week’s minor information hiccup had huge implications.

By Dave Nadig

How Ric Edelman is reinventing the ‘new economy’ investing paradigm.